Clinical Study Of IL-2 Treated Kidney Cancer

Background: Kidney cell cancer, also called kidney cancer, is one of usual malignancy in urinary system; the incidence is ranked No.2 in urinary tumors, 7th in all malignancies, and still increasing in these years. Basic research demonstrates that IL-2 is T cell growth factor, does not directly depress the activity of tumor cells, the anti-cancer mechanism is stimulating and activating the effective cells, amplifying the number of T cells, stimulating the growth of the activated T cells, strengthening patient's immuno-response, depressing the biological process, exerting the anti-cancer effects.Purpose: Discuss the effect of low dose IL-2 during and after radical nephrectomy in one side kidney cancer patients.Method: Retrospect analyzed 166 cases one side kidney cancer during 2003.01-2007.09 in China-Japan friendship hospital of Jilin University. The kidney function is normal before surgery, apply traditional loin cut radical nephrectomy, 77 cases received IL-2 during and after the surgery, all patients are followed up for a long term. Process the data with SPSS13.0 software, adopt Kaplan-Meier method to calculate survival rate, use Log-rank test to compare survival curve.Result: The median survival time is 45.000 months in IL-2 treated group (95% confidence interval is 44.090-45.910 months), 1, 2, 3 year survival rate are 97.4%, 90.9%, 75.3% respectively. The median survival time in group without IL-2 treatment is 41.000 months (95% confidence interval is 39.257-42.743 months), 1, 2, 3 year survival rate is 92.1%, 82%, 65.2% respectively. There is significant difference between the two survival curves (Log-rank test:χ2=6.766,P=0.009). In group without lymph node metastasis, the 1, 2, 3 year survival rate of IL-2 treated group are 98.6%, 93.0%, 77.5%. In group without IL-2 treatment, the 1, 2, 3 year survival rate are 91.9%, 81.4%, 64.0%. There is significant difference between the two survival curves (Log-rank test:χ2=9.659,P=0.002). In Bobsen stageⅠ, the 1, 2, 3 year survival rate of IL-2 treated group are 98.2%, 92.9%, 80.4%. In group without IL-2 treatment, the 1, 2, 3 year survival rate are 96.5%, 86.0%, 61.4%. There is significant difference between the two survival curves (Log-rank test:χ2=9.277,P=0.002).Conclusion: Radical nephrectomy and low dose IL-2 biological complementary therapy during and after surgery can improve the prognosis shortly, especially for group without lymph node metastasis and Robsen stage I patients.